Stock comparison
ELI LILLY & Co is 305.6x more valuable than Kiniksa Pharmaceuticals, Ltd. by market capitalization ($1.146 T vs $3.75 B). Compare market value, revenue, profit, margins, filings, and source pages in one place.
Quick answer
LLY is larger
ELI LILLY & Co is 305.6x more valuable than Kiniksa Pharmaceuticals, Ltd. by market capitalization ($1.146 T vs $3.75 B).
Market value leader
LLY
ELI LILLY & Co is 305.6x more valuable than Kiniksa Pharmaceuticals, Ltd. by market capitalization ($1.146 T vs $3.75 B).
Revenue leader
LLY
KNSA: $677.56M vs LLY: $65.18B.
Profit leader
LLY
KNSA: $59.01M vs LLY: $20.64B.
Margin leader
LLY
KNSA: 8.7% vs LLY: 31.7% net margin.
| Metric | KNSA | LLY |
|---|---|---|
| Market cap | $3.75 B | $1.146 T |
| US-listed rank | #1658 | #10 |
| Revenue (latest FY) | $677.56M | $65.18B |
| Net income (latest FY) | $59.01M | $20.64B |
| Net margin | 8.7% | 31.7% |
| P/E (trailing FY) | 63.6x | 55.5x |
| SEC filings | 733 | 995 |
Jump from this comparison into the underlying pages for market value, annual fundamentals, and company filing history.
Market cap uses refreshed market data. Revenue, net income, margins, and trailing fiscal-year P/E use annual company facts from filings. If a metric is missing, the source data did not have a clean recent annual value for that company.
ELI LILLY & Co is 305.6x more valuable than Kiniksa Pharmaceuticals, Ltd. by market capitalization ($1.146 T vs $3.75 B).
In their latest fiscal years, Kiniksa Pharmaceuticals, Ltd. reported $677.56M in revenue while ELI LILLY & Co reported $65.18B.
Full pages: Kiniksa Pharmaceuticals, Ltd. and ELI LILLY & Co, or browse the full rankings.